We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

220 hedge funds and large institutions have $4.68B invested in Blueprint Medicines in 2019 Q2 according to their latest regulatory filings, with 54 funds opening new positions, 94 increasing their positions, 46 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

104% more repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 46

59% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 34

59% more call options, than puts

Call options by funds: $63.8M | Put options by funds: $40.2M

20% more capital invested

Capital invested by funds: $3.89B → $4.68B (+$792M)

8% more funds holding

Funds holding: 203 → 220 (+17)

8.55% less ownership

Funds ownership: 110.07% → 101.52% (-8.5%)

27% less funds holding in top 10

Funds holding in top 10: 11 → 8 (-3)

Holders
220
Holders Change
+17
Holders Change %
+8.37%
% of All Funds
4.78%
Holding in Top 10
8
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-27.27%
% of All Funds
0.17%
New
54
Increased
94
Reduced
46
Closed
34
Calls
$63.8M
Puts
$40.2M
Net Calls
+$23.6M
Net Calls Change
+$25.6M

Top Buyers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
+$148M
2
BlackRock
BlackRock
New York
+$58.6M
3
HM
HealthCor Management
New York
+$31.6M
4
CCM
Cadian Capital Management
New York
+$26.7M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$26.6M

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$77.2M
2
TGI
TRV GP II
Massachusetts
-$70.4M
3
MWNA
Marshall Wace North America
New York
-$21.1M
4
LCM
Laurion Capital Management
New York
-$21M
5
CH
CVI Holdings
Delaware
-$16M
Name Holding Trade Value Shares
Change 		Change in
Stake
MIM
226
Monashee Investment Management
Massachusetts
– -$11.1M -138,500 Closed
Millennium Management
227
Millennium Management
New York
– -$6.08M -73,615 Closed
SI
228
Sofinnova Investments
California
– -$5.75M -71,866 Closed
BG
229
Bollard Group
Massachusetts
– -$3.79M -47,300 Closed
MS
230
Maven Securities
Jersey
– -$2.47M -30,700 Closed
ACM
231
Aquilo Capital Management
California
– -$2.45M -30,618 Closed
LCG
232
Lisanti Capital Growth
New York
– -$2.09M -26,150 Closed
JCM
233
JS Capital Management
New York
– -$2M -25,000 Closed
Hudson Bay Capital Management
234
Hudson Bay Capital Management
Connecticut
– -$1.6M -20,000 Closed
CM
235
Caption Management
Oklahoma
– -$1.49M -18,000 Closed
Assenagon Asset Management
236
Assenagon Asset Management
Luxembourg
– -$1.43M -17,846 Closed
HI
237
HBK Investments
Texas
– -$1.11M -13,900 Closed
VF
238
Virtu Financial
New York
– -$1M -12,531 Closed
PIM
239
Partner Investment Management
California
– -$782K -9,766 Closed
CSS
240
Cubist Systematic Strategies
Connecticut
– -$577K -7,212 Closed
PP
241
Paloma Partners
Connecticut
– -$557K -6,959 Closed
DCM
242
Dupont Capital Management
Delaware
– -$458K -5,725 Closed
HF
243
HRT Financial
New York
– -$412K -5,149 Closed
CIM
244
CIM Investment Management
Pennsylvania
– -$249K -3,105 Closed
WG
245
Winton Group
United Kingdom
– -$246K -3,077 Closed
SCM
246
Sio Capital Management
New York
– -$240K -3,000 Closed
NIT
247
NumerixS Investment Technologies
British Columbia, Canada
– -$30K -400 Closed
RFC
248
Regions Financial Corp
Alabama
– -$12K -150 Closed
OIA
249
Optimum Investment Advisors
Illinois
– -$8K -100 Closed
MNBTD
250
Moody National Bank Trust Division
Texas
– -$5K -63 Closed
7 8 9
10
11

BPMC Hedge Fund Activity: Q2 2019 in Review

220 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q2 2019, worth a combined $4.68B — up 20% from $3.89B a quarter earlier.

Buyers outnumbered sellers: 54 funds opened new BPMC positions and 34 closed out — a net gain of 20 holders — while 94 added to existing stakes and 46 trimmed.

The largest buyer was Invesco, adding an estimated $148M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $77.2M sold.

  • 220 institutional investors held Blueprint Medicines (BPMC) as of Q2 2019, up from 203 in Q1 2019.
  • Funds reported $4.68B of Blueprint Medicines stock for Q2 2019, up 20% quarter-over-quarter.
  • 54 funds opened new Blueprint Medicines positions in Q2 2019 and 34 closed out, a net change of +20 holders.
  • The largest Blueprint Medicines buyer in Q2 2019 was Invesco, an estimated $148M added.
  • The largest Blueprint Medicines seller in Q2 2019 was PFM Health Sciences, an estimated $77.2M sold.

Based on aggregated 13F filings for Q2 2019.